Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Shelley Abadi

Nurse Practitioner, Psychiatric/Mental Health Lakewood, CO Nurse Practitioner

NPI 1063801876 CMS profile 10742337

255 S Routt St Ste 250, Lakewood, CO 80228

Open in the dashboard

General payments

$19,073

195 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shelley Abadi of Lakewood, CO is reported in the CMS Open Payments database as having received $19,073 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,196 24
2024 General $8,665 47
2023 General $2,300 90
2022 General $913 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shelley Abadi
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Shelley Abadi were reported at $7,196. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Shelley Abadi Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $913 $195 $66–$559 $149
2023 $2,300 $233 $82–$673 $160
2024 $8,665 $236 $84–$688 $164
2025 $7,196 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Teva Pharmaceuticals USA, Inc. $15,645 71 payments
  2. Alkermes, Inc. $763 25 payments
  3. ITI, Inc. $434 12 payments
  4. AbbVie, Inc. $357 19 payments
  5. Otsuka America Pharmaceutical, Inc. $297 11 payments
  6. Tris Pharma Inc $295 6 payments
  7. Corium, Inc. $244 7 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $202 11 payments
  9. E.R. Squibb & Sons, L.L.C. $162 4 payments
  10. Ironshore Pharmaceuticals Inc. $114 6 payments
  11. Other $559 23 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,296 11 payments
  2. Food and Beverage $5,726 166 payments
  3. Travel and Lodging $985 17 payments
  4. Education $67 1 payment
Products named General payments · program years 2022–2025
  1. UZEDY $15,255 52 payments
  2. LYBALVI Cns $652 24 payments
  3. ARISTADA Cns $573 20 payments
  4. ARISTADA Cns $573 20 payments
  5. ARISTADA Cns $438 14 payments
  6. ARISTADA Cns $438 14 payments
  7. CAPLYTA $434 12 payments
  8. REXULTI $376 13 payments
  9. VRAYLAR $333 18 payments
  10. LYBALVI Cns $325 11 payments
  11. Other $2,635 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

709

Median for Nurse Practitioner: 389

Drug cost

$95,128

Median for Nurse Practitioner: $21,885

Branded share of claims

12.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 24 $79,944
Aripiprazole Generic 20 $2,712
Clozapine Generic 25 $1,709
Fluphenazine Decanoate Generic 13 $1,354
Olanzapine Generic 31 $1,182
Trazodone Hcl Generic 74 $771
Buspirone Hcl Generic 40 $766
Divalproex Sodium Generic 17 $568
Lithium Carbonate Er Lithium Carbonate Brand 24 $552
Lamotrigine Generic 47 $534

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$4,395

Medicare's payments for the services billed

Medicare patients

19

Average age 57

Services billed

56

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Atrial fibrillation 0%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UZEDY
  • Teva Pharmaceuticals USA, Inc. $8,053
$8,053 — —
CAPLYTA
  • ITI, Inc. $312
$312 — —
Dyanavel XR
  • Tris Pharma Inc $49
$49 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $42
$42 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record